The interaction between tumor and immune system plays a crucial role in cancer initiation, progression, and treatment. Cytolytic immune cells (T/NK cells) originally aim to recognize and kill cancer cells, whereas tumor tissue is capable of shaping the surrounding microenvironment to facilitate immune evasion. In particular, tumors can disrupt T/NK cell infiltration, T/NK cell function, and antigen presentation through soluble and cell-surface mediators (e.g. PD-L1) and immunosuppressive cells such as regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs). Therefore, elucidation of tumor and immune cell interplay would assist both the prediction of immunotherapy responses and the development of novel immunotherapy targets.
TISIDB is a web portal for tumor and immune system interaction, which integrates multiple heterogeneous data types. They pertain to:
Literature mining results from PubMed database.
High throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for detecting resistance and sensitivity of tumor cells to T cell-mediated killing.
Exome and RNA sequencing data set of patient cohorts with immunotherapy (responders and non-responders).
Genomics, transcriptomics and clinical data of 30 cancer types from The Cancer Genome Atlas (TCGA).
Public databases, including UniProt, GO, DrugBank etc.
These data are integrated into ten categories of information for each gene. Click here for more details. We believe TISIDB would become a valuable resource for cancer immunology research and therapy.